<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230125</url>
  </required_header>
  <id_info>
    <org_study_id>663</org_study_id>
    <nct_id>NCT01230125</nct_id>
  </id_info>
  <brief_title>Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery</brief_title>
  <official_title>Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to compare the safety and efficacy of Mapracorat&#xD;
      Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain&#xD;
      following cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.</measure>
    <time_frame>8 days</time_frame>
    <description>Anterior chamber (AC) cells were assessed using a 0 to 4 grading scale by an ophthalmologist using slip lamp biomicroscopy. A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens was performed without pupil dilation. Accumulation of white blood cells in aqueous was assessed. The grades were defined as: 0 = No cells seen; 1 = 1 - 5 cells; 2 = 6 - 15 cells; 3 = 16 - 30 cells; 4 = &gt;30 cells. Complete resolution of AC cells was defined as Grade 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Grade 0 Pain</measure>
    <time_frame>8 days</time_frame>
    <description>Ocular pain was defined as a positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. The scores ranged from 0=None to 5=Severe, were higher scores indicated worse pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Flare.</measure>
    <time_frame>8 days</time_frame>
    <description>A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens will be performed without pupil dilation. Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). The grades for flare were 0=None to 4=Very Severe effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Mapracorat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic suspension 3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of mapracorat ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mapracorat</intervention_name>
    <description>Instill study medication into study eye per dosing instructions for 14 days</description>
    <arm_group_label>Mapracorat</arm_group_label>
    <other_name>BOL-303242-X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Instill study medication into the study eye per dosing instructions for 14 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who are candidates for routine, uncomplicated cataract surgery&#xD;
&#xD;
          -  Participants who, in the Investigator's opinion, have potential postoperative pinhole&#xD;
             Snellen visual acuity (VA) of at least 20/200 in the study eye.&#xD;
&#xD;
          -  Participants must be willing to wait to undergo cataract surgery on the fellow eye&#xD;
             until after the study has been completed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are expected to require concurrent ocular therapy (either eye) with&#xD;
             nonsteroidal anti-inflammatory drugs (NSAIDs), mast cell stabilizers, antihistamines,&#xD;
             or decongestants.&#xD;
&#xD;
          -  Participants who are expected to require treatment with any systemic or ocular (either&#xD;
             eye) corticosteroids or glucocorticoids.&#xD;
&#xD;
          -  Participants who are expected to require concurrent ocular therapy with&#xD;
             immunosuppressants (eg, Restasis).&#xD;
&#xD;
          -  Participants who have known hypersensitivity or contraindication to the study drug(s)&#xD;
             or their components.&#xD;
&#xD;
          -  Participants participating in any drug or device clinical investigation within 30 days&#xD;
             prior to entry into this study and/or during the period of study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Ozden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb, Incorporated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2010</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <disposition_first_submitted>August 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 17, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 24, 2012</disposition_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Pain</keyword>
  <keyword>Ocular surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mapracorat</title>
          <description>Ophthalmic suspension 3%&#xD;
Mapracorat: Instill study medication into study eye per dosing instructions for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of mapracorat ophthalmic suspension&#xD;
Vehicle: Instill study medication into the study eye per dosing instructions for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mapracorat</title>
          <description>Ophthalmic suspension 3%&#xD;
Mapracorat: Instill study medication into study eye per dosing instructions for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of mapracorat ophthalmic suspension&#xD;
Vehicle: Instill study medication into the study eye per dosing instructions for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="311"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.2" spread="8.75"/>
                    <measurement group_id="B2" value="69.0" spread="7.53"/>
                    <measurement group_id="B3" value="69.1" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.</title>
        <description>Anterior chamber (AC) cells were assessed using a 0 to 4 grading scale by an ophthalmologist using slip lamp biomicroscopy. A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens was performed without pupil dilation. Accumulation of white blood cells in aqueous was assessed. The grades were defined as: 0 = No cells seen; 1 = 1 - 5 cells; 2 = 6 - 15 cells; 3 = 16 - 30 cells; 4 = &gt;30 cells. Complete resolution of AC cells was defined as Grade 0.</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mapracorat</title>
            <description>Ophthalmic suspension 3%&#xD;
Mapracorat: Instill study medication into study eye per dosing instructions for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of mapracorat ophthalmic suspension&#xD;
Vehicle: Instill study medication into the study eye per dosing instructions for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.</title>
          <description>Anterior chamber (AC) cells were assessed using a 0 to 4 grading scale by an ophthalmologist using slip lamp biomicroscopy. A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens was performed without pupil dilation. Accumulation of white blood cells in aqueous was assessed. The grades were defined as: 0 = No cells seen; 1 = 1 - 5 cells; 2 = 6 - 15 cells; 3 = 16 - 30 cells; 4 = &gt;30 cells. Complete resolution of AC cells was defined as Grade 0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Grade 0 Pain</title>
        <description>Ocular pain was defined as a positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. The scores ranged from 0=None to 5=Severe, were higher scores indicated worse pain.</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mapracorat</title>
            <description>Ophthalmic suspension 3%&#xD;
Mapracorat: Instill study medication into study eye per dosing instructions for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of mapracorat ophthalmic suspension&#xD;
Vehicle: Instill study medication into the study eye per dosing instructions for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Grade 0 Pain</title>
          <description>Ocular pain was defined as a positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. The scores ranged from 0=None to 5=Severe, were higher scores indicated worse pain.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Flare.</title>
        <description>A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens will be performed without pupil dilation. Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). The grades for flare were 0=None to 4=Very Severe effect.</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mapracorat</title>
            <description>Ophthalmic suspension 3%&#xD;
Mapracorat: Instill study medication into study eye per dosing instructions for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of mapracorat ophthalmic suspension&#xD;
Vehicle: Instill study medication into the study eye per dosing instructions for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Flare.</title>
          <description>A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens will be performed without pupil dilation. Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). The grades for flare were 0=None to 4=Very Severe effect.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mapracorat</title>
          <description>Ophthalmic suspension 3%&#xD;
Mapracorat: Instill study medication into study eye per dosing instructions for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of mapracorat ophthalmic suspension&#xD;
Vehicle: Instill study medication into the study eye per dosing instructions for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid macular edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Corneal edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

